TRIAL DETAIL
Pazopanib in Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib (PAGIST)
Drug: |
||||
|---|---|---|---|---|
Trial Name: |
Pazopanib in Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib (PAGIST) |
|||
NCT#: |
||||
Conditions: |
Gastrointestinal Stromal Tumor |
|||
Status: |
Completed |
|||
Phase: |
2 |
Start Date 02/01/2012 |
Age of Trial (yrs) 12.8 |
|
Treatment Phase: |
Gleevec-resistant |
|||
Drug Category: |
KIT/PDGFRA inhibitor+ VEGF inhibitor (TKI) |
|||
Strategy: |
Block KIT + Block blood vessel growth |
|||
Trial Type: |
Specifically GIST and only GIST |
|||
Other Protocol IDs: |
SSG XXI |
|||
Sponsor: |
Scandinavian Sarcoma Group |
|||
Patient Contact: |
Mikael H Eriksson, MD, PhD +46 46 171000 ext 77507 mikael.eriksson@med.lu.se |
|||
Contact email: |
||||
Contact Phone: |
||||
Randomized: |
||||
IV or Oral: |
Oral |
|||
Trial Notes: |
||||
Trial Links |
Trial Results |
Trial Sites
Name |
Address |
City |
State |
Zip |
Country |
Bergen |
N-5021 |
Norway |
|||
Oslo |
N-0310 |
Norway |
|||
Tromso |
N-9038 |
Norway |
|||
Trondheim |
N-7006 |
Norway |
|||
Gothenburg |
SE-413 45 |
Sweden |
|||
Linkoping |
SE-581 85 |
Sweden |
|||
Lund |
SE-221 85 |
Sweden |
|||
Stockholm |
SE-171 76 |
Sweden |
|||
Umea |
90185 |
Sweden |
|||
Uppsala |
SE-751 85 |
Sweden |